Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Total Non-Current Liabilities (2016 - 2023)

Historic Total Non-Current Liabilities for Alaunos Therapeutics (TCRT) over the last 11 years, with Q4 2023 value amounting to $2.0 million.

  • Alaunos Therapeutics' Total Non-Current Liabilities fell 9257.8% to $2.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $2.0 million, marking a year-over-year decrease of 9257.8%. This contributed to the annual value of $2.0 million for FY2023, which is 9257.8% down from last year.
  • Latest data reveals that Alaunos Therapeutics reported Total Non-Current Liabilities of $2.0 million as of Q4 2023, which was down 9257.8% from $5.5 million recorded in Q3 2023.
  • Alaunos Therapeutics' Total Non-Current Liabilities' 5-year high stood at $36.8 million during Q4 2021, with a 5-year trough of $2.0 million in Q4 2023.
  • For the 3-year period, Alaunos Therapeutics' Total Non-Current Liabilities averaged around $20.6 million, with its median value being $22.7 million (2022).
  • As far as peak fluctuations go, Alaunos Therapeutics' Total Non-Current Liabilities plummeted by 2840.34% in 2022, and later crashed by 9257.8% in 2023.
  • Over the past 3 years, Alaunos Therapeutics' Total Non-Current Liabilities (Quarter) stood at $36.8 million in 2021, then fell by 28.4% to $26.4 million in 2022, then tumbled by 92.58% to $2.0 million in 2023.
  • Its Total Non-Current Liabilities stands at $2.0 million for Q4 2023, versus $5.5 million for Q3 2023 and $6.3 million for Q2 2023.